Arbitral tribunal panel discards Adocia’s complaint against Eli Lilly
By Akshay Kedari  Date: 2019-08-24

Arbitral tribunal panel discards Adocia’s complaint against Eli Lilly

Following this move, Lilly would continue to focus on developing and discovering new treatments for people suffering from diabetes.

A Chicago-based arbitration panel has recently ruled in favor of U.S. pharma giant Eli Lilly and Co. in a claim filed by biotech firm Adocia S.A. over the companies' previous partnership on a rapid-acting insulin.

According to trusted sources, the panel comprising of three arbitrators lined a verdict claiming that Lilly acted appropriately regarding Adocia's intellectual property, but denied Lilly's smaller counterclaim ruling that the company is not liable for damages.

Commenting on the decision, Michael J. Harrington, Senior Vice President & General Counsel, Lilly, said that their firm is pleased with the panel's decision. He claims that their company conducts its business with integrity and is looking forward to putting this matter behind it and focusing on developing and discovering new treatments for people suffering from diabetes.

For the record, Adocia and Lilly inked a collaboration agreement in 2014. However, in 2017, Lilly terminated the agreement and halted its future manufacturing, commercialization and developments related to the program.

Apparently, Adocia filed claims against Lilly for misuse of its confidential information and advancements whereas Lilly filed counterclaims based on allegations that Adocia disguised those discoveries and confidential information which were issued in Adocia's claims.

Reports cite that the recent decision will not impact the 2018 verdict by the Tribunal to award Adocia USD 11.6 million in damages, including interest, as compensation over a disputed contractual milestone payment. Moreover, Adocia is expected to hold a conference call to answer shareholders’ questions in August 2019.

For the uninitiated, Lilly is one of the leading global health care firms that focus on clinical discoveries that make people’s life better across the world. The company employees work to develop life-changing medicines to patients, improves the management and understanding of disease, and helps communities through volunteerism and philanthropy.

Source Credit: https://www.businesswire.com/news/home/20190822005745/en/Adocia-Announces-American-Arbitration-Association-Tribunal-Dismissed

https://investor.lilly.com/news-releases/news-release-details/arbitration-panel-rules-favor-lilly-complaint-filed-adocia

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Rivian secures USD 2.65 billion months before its first vehicle launch
Rivian secures USD 2.65 billion months before its first vehicle launch
By Akshay Kedari

Electric vehicle startup, Rivian, backed by Ford Motor Co. and Amazon.com Inc., has reportedly announced an investment round of USD 2.65 billion led by T. Rowe Price, months before its first vehicle launch. Sources with knowledge of the matter state...

BMW drivers can now unlock and start cars without using their iPhone
BMW drivers can now unlock and start cars without using their iPhone
By Akshay Kedari

German multinational automobile manufacturer, Bayerische Motoren Werke AG, commonly known as BMW, has reportedly unveiled an upgraded version of its mobile car key technology, called the Digital Key Plus. This product enables iPhone users to unlock t...

FMCG firms resort to marginal hike to cope with raw material inflation
FMCG firms resort to marginal hike to cope with raw material inflation
By Akshay Kedari

The recent inflation in raw materials has reportedly prompted players in the FMCG sector to take price hike measures for their products, in a bid to maintain the revenues. According to reliable sources, some FMCG companies, including Marico, have al...

boAt raises USD 100 million in funding from Warburg Pincus
boAt raises USD 100 million in funding from Warburg Pincus
By Akshay Kedari

Indian consumer electronics brand, boAt, has reportedly secured funding of USD 100 million from Warburg Pincus, a New-York-based private equity firm, at a USD 300 million valuation. The company will utilize these funds to expand its product portfoli...

Elevar Therapeutics and Inceptua partner to commercialize Apealea®
Elevar Therapeutics and Inceptua partner to commercialize Apealea®
By Akshay Kedari

According to reliable sources, U.S.-based fully integrated biopharmaceutical company, Elevar Therapeutics Inc., has signed an exclusive agreement with Inceptua Group for the commercialization and distribution of its non-cremophor based paclitaxel tre...